Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
McKesson
Mallinckrodt
US Army
Argus Health
Farmers Insurance
Accenture
Covington
Queensland Health

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,361,649

« Back to Dashboard

Which drugs does patent 7,361,649 protect, and when does it expire?

Patent 7,361,649 protects CORLANOR and is included in one NDA.

This patent has forty-five patent family members in forty-one countries.
Summary for Patent: 7,361,649
Title:.beta.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Abstract: A .beta.-Crystalline form of ivabradine of formula (I): ##STR00001## characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Inventor(s): Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR)
Assignee: Les Laboratoires Servier (Courbevoie Cedex, FR)
Application Number:11/358,954
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,361,649

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-001 Apr 15, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE ➤ Sign Up
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-002 Apr 15, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,361,649

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 01985Feb 28, 2005

Non-Orange Book US Patents Family Members for Patent 7,361,649

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,879,842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,361,649

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Costa Rica 8248 ➤ Sign Up
Cuba 20060039 ➤ Sign Up
Cuba 23614 ➤ Sign Up
Cyprus 1109072 ➤ Sign Up
Germany 602006002624 ➤ Sign Up
Denmark 1695965 ➤ Sign Up
Eurasian Patent Organization 200600322 ➤ Sign Up
Ecuador SP066373 ➤ Sign Up
Eurasian Patent Organization 008464 ➤ Sign Up
Ecuador SP066375 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Merck
Accenture
Cerilliant
McKesson
Dow
Healthtrust
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot